Ajanta Pharma declares ₹32 interim dividend; Q1 FY27 Consolidated Revenue up 25% to ₹1,626 cr.
Ajanta Pharma reported Q1 FY27 consolidated revenue of ₹1,626 crore, up 25% YoY. PAT increased 31% to ₹334 crore. The board declared an interim dividend of ₹32 per share, totaling ₹400 crore. Key growth drivers included Branded Generics (up 13%) and US Generics (up 57%).
The substantial increase in revenue and profit, coupled with a significant interim dividend declaration, is a material event for shareholders and the market.
The company reported strong year-on-year growth in revenue and profit, along with a significant interim dividend payout, indicating a positive financial performance.
Ajanta Pharma Limited announced its financial results for the first quarter ended June 30, 2026, reporting a significant increase in both revenue and profit. The company's consolidated revenue from operations grew by 25% to ₹1,626 crore, compared to ₹1,303 crore in the same quarter last year. Profit After Tax (PAT) surged by 31% to ₹334 crore from ₹255 crore in Q1 FY26.
The Board of Directors has approved a first interim dividend of ₹32 per share for the financial year 2027, on shares with a face value of ₹2. This payout amounts to approximately ₹400 crore. The record date for this dividend payment has been fixed as Wednesday, August 5, 2026, with payments expected on or after August 18, 2026.
Key performance highlights for Q1 FY27 include an Adjusted EBITDA (excluding forex loss) of ₹454 crore, an increase of 21% from ₹377 crore in Q1 FY26. The company also reported a Return on Capital Employed (ROCE) of 37% and Return on Net Worth (RONW) of 28%.
Segment-wise, Branded Generics revenue grew by 13% to ₹1,059 crore, driven by strong performance in India (up 24% to ₹509 crore) and Africa (up 30% to ₹295 crore). US Generics showed exceptional growth, with revenue increasing by 57% to ₹487 crore. Africa Institution business also saw a significant jump of 83% to ₹70 crore.
The company's R&D expenses for the quarter were ₹66 crore, representing 4% of revenue. Ajanta Pharma highlighted its robust presence in over 34 countries and its focus on chronic therapies, with a strong product pipeline and market share gains in key segments. The company also detailed its financial results on a standalone basis, showing similar growth trends.
An earnings conference call was scheduled for July 30, 2026, at 16:15 hrs IST to discuss the financial performance.
What to do with a filing like this
Ajanta Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Ajanta Pharma Limited. Read the original for the full detail.